Kezar Life Sciences, Inc. (KZR) SEC Filing 8-K Material Event for the period ending Monday, December 20, 2021

Kezar Life Sciences, Inc.

CIK: 1645666 Ticker: KZR

View differences made from one to another to evaluate Kezar Life Sciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kezar Life Sciences, Inc..


Assess how Kezar Life Sciences, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kezar Life Sciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors



Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Ticker: KZR
CIK: 1645666
Form Type: 8-K Corporate News
Accession Number: 0001564590-21-060750
Submitted to the SEC: Mon Dec 20 2021 5:21:08 PM EST
Accepted by the SEC: Mon Dec 20 2021
Period: Monday, December 20, 2021
Industry: Pharmaceutical Preparations
  1. Earnings Release
  2. Ending Agreement

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: